Sherri-Ann M Burnett-Bowie

List of Publications by Year
in descending order

57 papers	4,542 citations	172207 29 h-index	161609 54 g-index
58 all docs	58 docs citations	58 times ranked	4789 citing authors

#	Article	IF	Citations
1	Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 2013, 369, 1011-1022.	13.9	621
2	Regulation of C-Terminal and Intact FGF-23 by Dietary Phosphate in Men and Women. Journal of Bone and Mineral Research, 2006, 21, 1187-1196.	3.1	407
3	Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. Lancet, The, 2015, 386, 1147-1155.	6.3	403
4	Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet, The, 2013, 382, 50-56.	6.3	384
5	Long-Term Follow-Up of Patients with Hypoparathyroidism. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4507-4514.	1.8	311
6	Two Years of Denosumab and Teriparatide Administration in Postmenopausal Women With Osteoporosis (The DATA Extension Study): A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1694-1700.	1.8	231
7	Post-transplant hypophosphatemia: Tertiary â€˜Hyper-Phosphatoninismâ€™?. Kidney International, 2006, 70, 1486-1494.	2.6	160
8	Gonadal steroidâ€“dependent effects on bone turnover and bone mineral density in men. Journal of Clinical Investigation, 2016, 126, 1114-1125.	3.9	148
9	Comparison of Weekly Treatment of Postmenopausal Osteoporosis with AlendronateVersusRisedronate Over Two Years. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2631-2637.	1.8	135
10	Effects of Teriparatide, Alendronate, or Both on Bone Turnover in Osteoporotic Men. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2882-2887.	1.8	130
11	Effects of Aromatase Inhibition on Bone Mineral Density and Bone Turnover in Older Men with Low Testosterone Levels. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4785-4792.	1.8	122
12	Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study. Journal of Bone and Mineral Research, 2015, 30, 39-45.	3.1	121
13	Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2915-2921.	1.8	115
14	Bone Health During the Menopause Transition and Beyond. Obstetrics and Gynecology Clinics of North America, 2018, 45, 695-708.	0.7	97
15	Prevalence and Predictors Ofvitamin D Deficiency in Healthy Adults. Endocrine Practice, 2012, 18, 914-923.	1.1	88
16	Clinical Measures Identify Vitamin D Deficiency in Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 460-467.	2.2	78
17	Effects of Teriparatide Retreatment in Osteoporotic Men and Women. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2495-2501.	1.8	72
18	Effects of hPTH(1-34) Infusion on Circulating Serum Phosphate, 1,25-Dihydroxyvitamin D, and FGF23 Levels in Healthy Men. Journal of Bone and Mineral Research, 2009, 24, 1681-1685.	3.1	71

#	Article	IF	Citations
19	Antimullerian Hormone and Impending Menopause in Late Reproductive Age: The Study of Womenâ€™s Health Across the Nation. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1862-e1871.	1.8	66
20	Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men. New England Journal of Medicine, 2013, 369, 2455-2457.	13.9	61
21	Effects of aromatase inhibition in hypogonadal older men: a randomized, doubleâ€blind, placeboâ€controlled trial. Clinical Endocrinology, 2009, 70, 116-123.	1.2	57
22	The biology and pathology of vitamin D control in bone. Journal of Cellular Biochemistry, 2010, 111, 7-13.	1.2	55
23	Addressing the Elephant in the Room: Microaggressions in Medicine. Annals of Emergency Medicine, 2020, 76, 387-391.	0.3	46
24	Randomized Trial Assessing the Effects of Ergocalciferol Administration on Circulating FGF23. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 624-631.	2.2	45
25	Menstrual Cycle Hormone Changes in Women Traversing Menopause: Study of Womenâ€™s Health Across the Nation. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2218-2229.	1.8	41
26	Serum 25 Hydroxyvitamin D, Bone Mineral Density and Fracture Risk Across the Menopause. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2046-2054.	1.8	38
27	Bone and the Perimenopause. Obstetrics and Gynecology Clinics of North America, 2011, 38, 503-517.	0.7	34
28	Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. Bone, 2007, 40, 913-918.	1.4	33
29	Insulin secretion and sensitivity in healthy adults with low vitamin D are not affected by high-dose ergocalciferol administration: a randomized controlled trial. American Journal of Clinical Nutrition, 2015, 102, 385-392.	2.2	33
30	Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial. Journal of Clinical Densitometry, 2016, 19, 346-351.	0.5	29
31	Effect of Physician-Delivered COVID-19 Public Health Messages and Messages Acknowledging Racial Inequity on Black and White Adultsâ€™ Knowledge, Beliefs, and Practices Related to COVID-19. JAMA Network Open, 2021, 4, e2117115.	2.8	27
32	FGF23 Is Not Associated With Age-Related Changes in Phosphate, but Enhances Renal Calcium Reabsorption in Girls. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1151-1160.	1.8	24
33	Changes in Regional Fat Distribution and Anthropometric Measures Across the Menopause Transition. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2520-2534.	1.8	23
34	Prediction of Changes in Bone Mineral Density in Postmenopausal Women Treated with Once-Weekly Bisphosphonates. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 1097-1103.	1.8	22
35	Disparities in Reproductive Aging and Midlife Health between Black and White women: The Study of Womenâ€™s Health Across the Nation (SWAN). Women's Midlife Health, 2022, 8, 3.	0.5	22
36	Association Between Resident Race and Ethnicity and Clinical Performance Assessment Scores in Graduate Medical Education. Academic Medicine, 2022, 97, 1351-1359.	0.8	19

#	Article	IF	Citations
37	Teaching Medical Students How to Ask Patients Questions About Identity, Intersectionality, and Resilience. MedEdPORTAL: the Journal of Teaching and Learning Resources, 2016, 12, 10422.	0.5	17
38	Dose-Response Relationships Between Gonadal Steroids and Bone, Body Composition, and Sexual Function in Aging Men. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 2779-2788.	1.8	15
39	This is our lane: talking with patients about racism. Women's Midlife Health, 2021, 7, 7.	0.5	15
40	Associations of Age at Menopause With Postmenopausal Bone Mineral Density and Fracture Risk in Women. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e561-e569.	1.8	15
41	Trabecular Bone Morphology Correlates With Skeletal Maturity and Body Composition in Healthy Adolescent Girls. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 336-345.	1.8	14
42	Disparities in osteoporosis care among postmenopausal women in the United States. Maturitas, 2022, 156, 25-29.	1.0	13
43	Serum Sex Hormones and the Risk of Fracture Across the Menopausal Transition: Study of Womenâ€™s Health Across the Nation. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2412-2418.	1.8	9
44	The USPSTF 2021 Recommendations on Screening for Asymptomatic Vitamin D Deficiency in Adults. JAMA - Journal of the American Medical Association, 2021, 325, 1401.	3.8	8
45	Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2718-2723.	1.8	7
46	Age-Related Changes in Bone Density, Microarchitecture, and Strength in Postmenopausal Black and White Women: The SWAN Longitudinal HR-pQCT Study. Journal of Bone and Mineral Research, 2020, 37, 41-51.	3.1	7
47	Temporal increases in 25â€hydroxyvitamin D in midlife women: Longitudinal results from the Study of Womenâ€™s Health Across the Nation. Clinical Endocrinology, 2019, 91, 48-57.	1.2	6
48	Attitudes and Actions Related to Racism: the Anti-RaCism (ARC) Survey Study. Journal of General Internal Medicine, 2022, 37, 2337-2344.	1.3	6
49	Development and analytical validation of a novel bioavailable 25-hydroxyvitamin D assay. PLoS ONE, 2021, 16, e0254158.	1.1	5
50	Using a Virtual Platform to Teach Residents How to Respond to Bias. Journal of General Internal Medicine, 2022, 37, 2871-2872.	1.3	5
51	An Unusual Case of Primary Hyperparath Yroidism with Profoundly Elevated Parath Yroid Hormone Levels. Endocrine Practice, 2008, 14, 892-897.	1.1	4
52	Racism: the shameful practices that the medical profession is finally addressing. Women's Midlife Health, 2021, 7, 9.	0.5	3
53	Is twice-yearly denosumab beneficial in postmenopausal women with osteopenia but no history of fracture?. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 660-661.	2.9	2
54	Anti-Mullerian Hormone as Predictor of Future and Ongoing Bone Loss During the Menopause Transition. Journal of Bone and Mineral Research, 2020, 37, 1224-1232.	3.1	2

#	Article	IF	Citations
55	Vitamin D and fat. Menopause, 2009, 16, 637-638.	0.8	0
56	Correspondence. Annals of Emergency Medicine, 2021, 77, 382-383.	0.3	0
57	Leadership & Professional Development: Breaking the Silence as a Bystander. Journal of Hospital Medicine, 2020, 15, 598-598.	0.7	0